Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Down 57.8% in December

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totalling 2,700 shares, a drop of 57.8% from the November 30th total of 6,400 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 20,000 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $8.00 price objective on shares of Anebulo Pharmaceuticals in a report on Tuesday, November 19th.

Anebulo Pharmaceuticals Stock Performance

Shares of Anebulo Pharmaceuticals stock traded up $0.08 during mid-day trading on Friday, hitting $1.70. 88,982 shares of the stock were exchanged, compared to its average volume of 10,907. Anebulo Pharmaceuticals has a 12 month low of $0.80 and a 12 month high of $3.30. The company has a 50-day simple moving average of $1.57 and a 200 day simple moving average of $1.93. The company has a market capitalization of $44.09 million, a P/E ratio of -5.67 and a beta of -1.09.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last issued its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Analysts predict that Anebulo Pharmaceuticals will post -0.52 EPS for the current year.

Insider Activity

In related news, Director Aron R. English bought 10,101,010 shares of the business’s stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average price of $0.99 per share, with a total value of $9,999,999.90. Following the completion of the transaction, the director now directly owns 15,467,300 shares in the company, valued at approximately $15,312,627. This represents a 188.23 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 85.90% of the company’s stock.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.